Human monoclonal antibodies against the rhesus D antigen from women with severe Rh immunization submitted to high-dose intravenous immunoglobulin treatment.
The pre- and postpartum maternal serum anti-D concentrations of 28 women with severe Rh(D) immunization who received high-dose intravenous immunoglobulin treatment has been determined. In all cases, including 1 in which the newborn was D negative, a sharp increment in the anti-D titer was observed after delivery. The specific immunoglobulin concentration rose to levels ranging from 4.7 to 204.0 micrograms/ml and, in 20% of the patients, increments of fifty times or greater were observed. Human monoclonal antibodies (hmAb) have been produced from Epstein-Barr virus-transformed lymphoblastoid B cell lines derived from 1 of these naturally hyperimmunized patients whose serum contained an anti-D-category DVI antibody. Four anti-D-secreting cell lines (97.E3.39.214, 44.E4.R1.257, E7.R1.126.83.115 and E11V.117.63; hereafter referred to as 214, 257, 115 and 63) have been established and maintained in continuous culture for periods ranging from several months to 3 years, without loss of antibody production capacity. Antibodies 115 and 214 recognize all Du samples tested at the same level as the polyclonal positive control. Antibodies 63 and 257 show a significantly lower reaction strength with some of the Du samples. Studies with D category cells showed that the DVI category was recognized only by hmAb 214. The reactivity pattern of this antibody is that of an anti-epD4, although the reaction strength varied greatly with different DIVa cell samples. Results obtained with hmAb 257 and 115 using papain-treated D category cells suggest that booth react as anti-epD6/7.(ABSTRACT TRUNCATED AT 250 WORDS)
del Aguila
C
C
Kabi-Pharmacia Institute of Biotechnology, Hospital La Paz, Madrid, Spain.
Guillén
M V
MV
de la Cámara
C
C
Llopis
R
R
D000911:Antibodies, Monoclonal / Q000097:blood / Q000302:isolation & purification*; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000276:immunology; D002461:Cell Line, Transformed; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology / Q000302:isolation & purification*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood* / Q000276:immunology / Q000628:therapy; D011644:Puerperal Disorders / Q000097:blood* / Q000276:immunology; D012203:Rh Isoimmunization / Q000097:blood / Q000276:immunology / Q000628:therapy*; D018029:Rho(D) Immune Globulin / Q000097:blood / Q000302:isolation & purification*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D018029:Rho(D) Immune Globulin